Gastro-oesophageal reflux disease: extinguishing that fire
Gastro-oesophageal reflux disease (GORD) is a highly prevalent, chronic disorder. Information regarding this disease is limited and the management of these patients changes continuously. Proton-pump inhibitors (PPIs) remain the first-choice therapy in the treatment of GORD, but a consistent proportion of these patients continue to experience symptoms despite their use. Currently, other available agents include simple antacids and acid suppression therapy, including histamine 2-receptor antagonists (H2RAs), mucosal or cytoprotective agents and pro-motility agents. Recently, several new drugs have been used to increase the defensive properties of the gastric mucosa with promising results in randomised clinical trials. Deciding on appropriate therapy will depend on the diagnosis, side-effects and cost-effectiveness of the treatment.